Company profile: Vergent Bio
1.1 - Company Overview
Company description
- Provider of tumor-targeted molecular imaging solutions for cancer surgery, including VGT-309, a fluorescent agent that binds to cathepsins in solid tumors to enable real-time visualization during minimally invasive and robotic-assisted procedures, improving detection and removal of cancerous tissue. Conducts clinical studies evaluating VGT-309’s efficacy and safety in lung cancer surgeries, with potential application in other solid tumors.
Products and services
- VGT-309: Builds a cathepsin-binding fluorescent imaging agent enabling real-time visualization of solid tumors during minimally invasive and robotic-assisted cancer surgeries, enhancing detection and removal of cancerous tissue
- Clinical Studies on VGT-309: Executes lung cancer-specific research evaluating the efficacy and safety of VGT-309 in surgeries, with potential application to other solid tumors
- Tumor-Targeted Molecular Imaging Molecules Development: Develops tumor-targeted molecular imaging molecules for cancer surgery, creating agents to visualize tumors during surgery and enhance surgeon detection and removal of cancerous tissue
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vergent Bio
Gentian Diagnostics
HQ: Sweden
Website
- Description: Provider of manufacturing of anti corps and other components of biochemical raw materials for the medical diagnostics industry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gentian Diagnostics company profile →
Toolbox Medical
HQ: United States
Website
- Description: Provider of point-of-care in vitro diagnostic (IVD) product development, usability testing, clinical research, and manufacturing services. Supports clients from initial concept to final product, ensuring user-friendly, cost-effective, clinically validated devices and diagnostics that meet regulatory requirements and comply with industry standards.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Toolbox Medical company profile →
Cylex
HQ: United States
Website
- Description: Provider of in vitro diagnostic products designed to illuminate immunity in transplant medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cylex company profile →
Medix Biochemica
HQ: Finland
Website
- Description: Provider of critical raw materials to the in vitro diagnostics (IVD) industry; a global, market-leading supplier enabling IVD customers to deliver accurate results to billions of patients worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medix Biochemica company profile →
Elitech
HQ: France
Website
- Description: Provider of in vitro diagnostic equipment, reagents, and software for clinical and research laboratories, offering molecular diagnostics, clinical chemistry benchtop analyzers, microbiology solutions, and biomedical systems. Portfolio includes Selectra Mach5 and Selectra Pro & Mach5 systems with ready-to-use reagents, calibrators, controls, and consumables.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elitech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vergent Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vergent Bio
2.2 - Growth funds investing in similar companies to Vergent Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vergent Bio
4.2 - Public trading comparable groups for Vergent Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →